ASCO 2019: Atezolizumab + Bevacizumab Versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology: IMmotion151 Subgroup Analysis – Medical Oncologist Perspective

ASCO 2019 IMmotion 151, atezolizumab plus bevacizumab versus sunitinib, patients with mRCC, proven strategy for patients with mRCC, sarcomatoid histology, patients with sarcomatoid features.

Read the full article here

Related Articles